IRadimed Corp
NASDAQ:IRMD

Watchlist Manager
IRadimed Corp Logo
IRadimed Corp
NASDAQ:IRMD
Watchlist
Price: 96.11 USD -1.3% Market Closed
Market Cap: 1.2B USD

IRadimed Corp
Investor Relations

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging (MRI) compatible medical devices. The company is headquartered in Winter Springs, Florida and currently employs 110 full-time employees. The company went IPO on 2014-07-16. Its MRidium 3860+ MRI Compatible IV infusion pump system provides non-magnetic Intravenous (IV) infusion pump system that is specifically designed for safe use during MRI procedures. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor with non-ferrous parts and other special features to deliver anesthesia safely and predictably and other IV medications or fluids during various MRI procedures. Its IRadimed 3880 MRI Compatible patient vital signs monitoring system has been designed with non-magnetic components and other features to monitor a patient’s vital signs safely and accurately during various MRI procedures. The firm sells its products primarily to hospitals and acute care facilities, both in the United States and internationally.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q3 2025
Call Date
Nov 3, 2025
AI Summary
Q3 2025

Record Revenue: IRADIMED posted its 17th consecutive quarter of record revenue, reaching $21.2 million for Q3 2025, up 16% from last year.

Pumps & Monitoring Growth: MRI IV pump sales grew 20% year-over-year; MRI patient monitor shipments increased 16%, driving strong overall results.

Gross Margin Strength: Gross margin held at 78% despite manufacturing transition, slightly improving from last year and above expectations.

Guidance Raised: Full-year 2025 revenue guidance increased to $82.5–83.5 million (up from $80–82.5 million); EPS guidance also raised.

3870 Pump Launch: Commercial U.S. launch of the new 3870 MRI IV pump will begin in January 2026, targeting a step-change in pump revenue, especially from replacements.

International Expansion: 3870 launch in Europe and Japan is expected in 2027 after regulatory approvals.

Capacity Secured: New facility is 2.5 times larger and can support significant growth, with room to expand further.

Key Financials
Revenue
$21.2 million
Gross Profit
$16.4 million
Gross Margin
78%
Operating Expenses
$9.7 million
Income from Operations
$6.8 million
Tax Expense
$1.7 million
Net Income
$5.6 million
Earnings Per Share (Diluted)
$0.43
Cash and Cash Equivalents
$56.5 million
Cash Flow from Operations
$7 million
Free Cash Flow
$5.7 million
Quarterly Dividend
$0.17 per share
MRI IV Pump Revenue
$8.3 million
Patient Vital Signs Monitoring Revenue
$6.9 million
Disposable Revenue
$4.1 million
Domestic Sales
$18.1 million
International Sales
$3.1 million
Earnings Call Recording
Other Earnings Calls

Management

Mr. Roger E. Susi
Founder, Chairman, CEO & President
No Bio Available
Mr. John F. Glenn
CFO & Corporate Secretary
No Bio Available
Mr. Randy Waddell
Vice President of Worldwide Sales & Marketing
No Bio Available
Mr. Chris Williamson
Executive Vice President of Continuous Improvement & Information Technology
No Bio Available
Mr. Matt Garner
Controller
No Bio Available
Mr. Steve Kachelmeyer
Vice President of Regulatory Affairs & Quality Assurance
No Bio Available
Mr. Lynn Neuhardt
Vice President of Research & Development
No Bio Available

Contacts

Address
FLORIDA
Winter Springs
1025 Willa Springs Dr
Contacts
+14076778022.0
www.iradimed.com